Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, PO Box 14115-111, Tehran, Islamic Republic of Iran.
Clin Biochem. 2012 Apr;45(6):385-96. doi: 10.1016/j.clinbiochem.2012.01.017. Epub 2012 Jan 27.
There are several issues to be considered to reduce the risk of rejection and minimize side effects associated with liver cell transplantation in chronic liver diseases. The source and the condition of stem cell proliferation and differentiation ex vivo and the transplantation protocols are important safety considerations for cell based therapy. The biochemical and molecular markers are important tools for safety evaluation of different processes of cell expansion and transplantation. Studies show that hepatocytes differentiated from adult and embryonic stem cells exhibit biochemical and metabolic properties resembling mature hepatocytes. Therefore these assays can help to assess the biological and metabolic performance of hepatocytes and progenitor stem cells. The assays also help in testing the contribution of transplanted hepatocytes in improving the repair and function of damaged liver in the recipient. Here we review the biochemical and metabolic markers, which are implicated in evaluation of safety issues of stem cells used for therapeutic purposes in chronic liver diseases and regeneration of damaged liver. We also highlight application of biochemical tests for assessment of liver cell transplantation.
有几个问题需要考虑，以降低慢性肝病中肝细胞移植的排斥风险和最小化相关副作用。干细胞在体外的增殖和分化的来源和状态以及移植方案是细胞治疗的重要安全性考虑因素。生化和分子标志物是细胞扩增和移植不同过程的安全性评估的重要工具。研究表明，来源于成体和胚胎干细胞的肝细胞表现出类似于成熟肝细胞的生化和代谢特性。因此，这些检测可以帮助评估肝细胞和祖细胞的生物学和代谢性能。这些检测还可以帮助检测移植的肝细胞在改善受者受损肝脏的修复和功能方面的作用。在这里，我们综述了生化和代谢标志物，这些标志物与评估用于慢性肝病治疗和受损肝脏再生的干细胞的安全性问题有关。我们还强调了生化检测在评估肝细胞移植中的应用。
